John F. Thompson
约翰·汤普森
MD, FRACS, FACS
Medical Director Emeritus, Melanoma Institute Australia; Conjoint Professor of Melanoma Surgery澳大利亚黑色素瘤研究所名誉医疗主任；黑色素瘤外科联合教授
👥Biography 个人简介
John Thompson, MD, FRACS, FACS is Medical Director Emeritus of the Melanoma Institute Australia and is globally regarded as one of the founders of modern melanoma surgical oncology. He played a central role in establishing sentinel lymph node biopsy as the standard staging procedure for melanoma through the landmark MSLT-I and MSLT-II trials, and has trained generations of melanoma surgeons worldwide. His career of over 40 years has produced the most comprehensive evidence base for surgical management of primary and metastatic melanoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Sentinel Lymph Node Biopsy: MSLT-I and MSLT-II Trials
Key investigator in the Multicenter Selective Lymphadenectomy Trial (MSLT-I) establishing sentinel lymph node biopsy as the standard staging procedure, and MSLT-II demonstrating that observation after positive SLNB was non-inferior to immediate completion lymph node dissection, sparing thousands of patients unnecessary surgery.
Melanoma Surgical Oncology Training and Standardization
Established and led the largest melanoma surgical program in the Southern Hemisphere at the Sydney Melanoma Unit / Melanoma Institute Australia, training hundreds of surgeons and standardizing excision margins, SLNB technique, and follow-up protocols adopted worldwide.
Prognostic Factors and Staging in Melanoma
Made fundamental contributions to AJCC melanoma staging through analysis of large surgical databases, defining the prognostic roles of Breslow thickness, ulceration, and mitotic rate that remain central to current staging systems.
Representative Works 代表性著作
Sentinel-node biopsy or nodal observation in melanoma (MSLT-II)
New England Journal of Medicine (2017)
Landmark phase III trial demonstrating no melanoma-specific survival benefit from completion lymph node dissection after positive sentinel node biopsy, fundamentally changing surgical management of stage III melanoma.
Final trial report of sentinel-node biopsy versus nodal observation in melanoma (MSLT-I)
New England Journal of Medicine (2014)
Long-term results of the first MSLT trial establishing sentinel lymph node biopsy as the standard staging procedure and demonstrating a melanoma-specific survival benefit in the intermediate-thickness subgroup.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 约翰·汤普森 的研究动态
Follow John F. Thompson's research updates
留下邮箱，当我们发布与 John F. Thompson（Melanoma Institute Australia / University of Sydney）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment